Skip to content

Study · Systematic review · 2019

3 results

Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.

Cheng L, Hu Y, Li YY, Cao X, Bai N, Lu TT, Li GQ, Li N, Wang AN, Mao XM

Diabetes/metabolism research and reviews6 May 2019Cited by 87 (Europe PMC)

PMID30974033 (opens in a new tab)DOI10.1002/dmrr.3168 (opens in a new tab)PepBankPUB-30974033
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In patients with type 2 diabetes, liraglutide treatment was associated with a significantly lower bone fracture risk (OR 0.56).

    In plain wordsIn adults with type 2 diabetes, liraglutide was linked to fewer bone fractures than placebo or other diabetes drugs.

    Peptide
    Liraglutide
    Outcome
    DecreaseBone fracture risk, liraglutide
    Study

    n: not reported in source

    Comparator
    Placebo or other anti-diabetic drugs
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Odds ratio
    0.56 ratio
    liraglutide

    Source sentences

    Summary
    Subgroup analysis showed that treatments with liraglutide and lixisenatide were associated with significantly reduced risk of bone fractures (ORs, 0.56; 95% CI, 0.38-0.81 and 0.55; 95% CI, 0.31-0.97, respectively).
    1 context sentence
    Summary · context
    We conducted a systematic literature search in PubMed, Embase, the Cochrane Library, and Web of Science from inception to 28 February 2018 and identified eligible randomized controlled trials.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In patients with type 2 diabetes, GLP-1 receptor agonists (including liraglutide) were associated with lower bone fracture risk than placebo or other anti-diabetic drugs (pooled OR 0.71).

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group were linked to fewer bone fractures than placebo or other diabetes drugs.

    Peptide
    Liraglutide
    Outcome
    DecreaseBone fracture risk, all GLP-1 RAs
    Study

    n = 39,795

    Comparator
    Placebo or other anti-diabetic drugs
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Odds ratio
    0.71 ratio
    GLP-1 RAs vs control

    Source sentences

    Summary
    Compared with patients who received placebo and other anti-diabetic drugs, those who received GLP-1 RAs treatment showed a pooled OR of 0.71 (95% CI, 0.56-0.91) for bone fracture.
    1 context sentence
    Summary · context
    We conducted a systematic literature search in PubMed, Embase, the Cochrane Library, and Web of Science from inception to 28 February 2018 and identified eligible randomized controlled trials.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In patients with type 2 diabetes, only GLP-1 receptor agonist treatment longer than 52 weeks significantly lowered bone fracture risk (OR 0.71).

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs were linked to fewer fractures only when used for more than 52 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseBone fracture risk, treatment longer than 52 weeks
    Study

    n: not reported in source

    Comparator
    Placebo or other anti-diabetic drugs
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Odds ratio
    0.71 ratio
    treatment >52 weeks

    Source sentences

    Summary
    Moreover, these beneficial effects were dependent on the duration of GLP-1 RAs treatment, only a GLP-1 RAs treatment period of more than 52 weeks could significantly lower the risk of bone fracture in patients with T2DM (OR, 0.71; 95% CI, 0.56-0.91).
    1 context sentence
    Summary · context
    We conducted a systematic literature search in PubMed, Embase, the Cochrane Library, and Web of Science from inception to 28 February 2018 and identified eligible randomized controlled trials.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    9 Oct 2026, 18:17 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.